Natalia Rozhkovska
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Natalia Rozhkovska has a total of 137 co-authors. Here are the top co-authors by number of shared publications:
- Igor Z. Gladchuk
Odesa national medical university, Odesa
8 shared publications - N. F. Zakharenko
SSI «Center for Innovative Medical Technologies of the NAS of Ukraine», Kyiv
6 shared publications - Nataliia V. Kosei
SSI «Center of Innovative Medical Technologies of the NAS of Ukraine»; SI «Ukrainian Center of Motherhood and Childhood of the NAMS of Ukraine», Kyiv
6 shared publications - O.G. Yashina
Medikom Clinic, Kyiv
6 shared publications - Tatyana F. Tatarchuk
SI “Ukrainian Center of Motherhood and Childhood of the NAMS of Ukraine”; SSI “Center for Innovative Medical Technologies of the NAS of Ukraine”, Kyiv
6 shared publications - Nataliia Pedachenko
P.L. Shupyk National University of Health Care of Ukraine, Kyiv
5 shared publications
Latest Publications
- Open Access
- 30 September 2026
- Published by Publishing Office TRILIST in Reproductive Endocrinology
- No. 85,p. 68-72
Clinical and anamnestic characteristics of infertile patients with ovarian endometriomas in assisted reproductive technology programs
Objective of the study: to evaluate the clinical, anamnestic, reproductive, and hormonal characteristics of infertile patients with ovarian endometriomas depending on prior surgical treatment in assisted reproductive technology.Materials and methods. A retrospective cohort study was conducted involving 67 infertile patients who underwent evaluation and treatment using assisted reproductive technology programs between 2024 and 2026. Group 1 included 24 patients with ovarian endometriomas following surgical treatment; Group 2 included 23 patients with untreated ovarian endometriomas; and Group 3, the control group, included 20 patients with male-factor and/or absolute tubal infertility without endometriosis. Results. No statistically significant differences in age were found between the groups. At the same time, the groups differed in body mass index, age at menarche, and duration of infertility. Primary infertility was more common in patients with ovarian endometriomas, whereas secondary infertility predominated in the control group. Patients with endometriomas typically presented with dysmenorrhea and pre- and postmenstrual bleeding. The highest incidence of dysmenorrhea was observed in the group with untreated endometriomas. Regarding hormonal profile indicators, statistically significant differences were found in the levels of anti-Müllerian hormone and estradiol. The lowest anti-Müllerian hormone level was found in patients with endometriomas (0.61 ± 0.07 ng/mL), whereas in patients who had undergone surgical treatment it was 1.67 ± 0.28 ng/mL, and in the control group – 1.38 ± 0.14 ng/mL. Estradiol levels were highest in Group 2 – 143.5 ± 40.1 pg/mL. Conclusions. Infertile patients with ovarian endometriomas exhibit characteristic clinical and anamnestic features, including a higher prevalence of primary infertility, dysmenorrhea, and menstrual cycle disorders. The presence of untreated ovarian endometriomas was associated with a statistically significant decrease in anti-Müllerian hormone levels and an increase in estradiol levels. The results confirm the need for an individualized assessment of reproductive potential and ovarian reserve when planning assisted reproductive technology in patients with ovarian endometriomas.
- 30 September 2026
- Published by Publishing Office TRILIST in Reproductive Endocrinology
- No. 85,p. 68-72
Open AccessClinical and anamnestic characteristics of infertile patients with ovarian endometriomas in assisted reproductive technology programs
Objective of the study: to evaluate the clinical, anamnestic, reproductive, and hormonal characteristics of infertile patients with ovarian endometriomas depending on prior surgical treatment in assisted reproductive technology.Materials and methods. A retrospective cohort study was conducted involving 67 infertile patients who underwent evaluation and treatment using assisted reproductive technology programs between 2024 and 2026. Group 1 included 24 patients with ovarian endometriomas following surgical treatment; Group 2 included 23 patients with untreated ovarian endometriomas; and Group 3, the control group, included 20 patients with male-factor and/or absolute tubal infertility without endometriosis. Results. No statistically significant differences in age were found between the groups. At the same time, the groups differed in body mass index, age at menarche, and duration of infertility. Primary infertility was more common in patients with ovarian endometriomas, whereas secondary infertility predominated in the control group. Patients with endometriomas typically presented with dysmenorrhea and pre- and postmenstrual bleeding. The highest incidence of dysmenorrhea was observed in the group with untreated endometriomas. Regarding hormonal profile indicators, statistically significant differences were found in the levels of anti-Müllerian hormone and estradiol. The lowest anti-Müllerian hormone level was found in patients with endometriomas (0.61 ± 0.07 ng/mL), whereas in patients who had undergone surgical treatment it was 1.67 ± 0.28 ng/mL, and in the control group – 1.38 ± 0.14 ng/mL. Estradiol levels were highest in Group 2 – 143.5 ± 40.1 pg/mL. Conclusions. Infertile patients with ovarian endometriomas exhibit characteristic clinical and anamnestic features, including a higher prevalence of primary infertility, dysmenorrhea, and menstrual cycle disorders. The presence of untreated ovarian endometriomas was associated with a statistically significant decrease in anti-Müllerian hormone levels and an increase in estradiol levels. The results confirm the need for an individualized assessment of reproductive potential and ovarian reserve when planning assisted reproductive technology in patients with ovarian endometriomas.
- Open Access
- 2 July 2026
- Published by Publishing Office TRILIST in Reproductive Endocrinology
- No. 84,p. 41-48
Cytomorphological criteria for the differential diagnosis of endometrial hyperplasia and endometrial cancer
Objective of the study: to establish an optimal set of cytological criteria and to develop a mathematical algorithm to improve the effectiveness of the differential diagnosis of endometrial hyperplasia and cancer.Materials and methods. A preoperative examination of the endometrium was carried out in 32 patients with abnormal uterine bleeding by means of aspiration cytology, using a standardized assessment algorithm comprising 7 most informative cytomorphological features. Based on mathematical analysis and Bayes’ theorem, an expert diagnostic system was developed, defining weighting coefficients and threshold values for differentiating between endometrial hyperplasia and endometrial cancer. The cytology findings were verified by the results of the post-operative histological examination.Results. The comprehensive use of standardized cytological criteria in combination with a mathematical algorithm improves the accuracy of the differential diagnosis of hyperplastic and malignant processes of the endometrium. The most significant cytological criteria for differential diagnosis were found to be impaired cell polarity within structures, an increased nuclear-cytoplasmic index, abnormal nuclear and nucleolar shapes, irregular nuclear membranes, neoplastic features and the formation of three-dimensional cell structures. In the group of women aged 30–39 years, a low prevalence of endometrial cancer was confirmed. The summary coefficient did not reach the threshold level. In the 40–49 age group, an increase in the frequency of endometrial hyperplastic processes, polyps and abnormal uterine bleeding was observed. It was in this group that the first case of endometrial carcinoma was recorded. In the patient with a malignant endometrial tumor, the summary diagnostic coefficient significantly exceeded the threshold value (+195), indicating the presence of a complex of cytomorphological features characteristic of malignant transformation of the endometrium. In women aged 60–69 years, endometrial pathology was represented by both glandular hyperplasia and endometrial cancer. The total diagnostic coefficient significantly exceeded the established diagnostic threshold.Conclusions. The results obtained support the comprehensive use of cytological criteria and a mathematical algorithm for differential diagnosis, which helps to improve the accuracy of detecting precancerous and malignant changes in the endometrium and may be recommended for implementation in cytology laboratories and clinical settings.
- 2 July 2026
- Published by Publishing Office TRILIST in Reproductive Endocrinology
- No. 84,p. 41-48
Open AccessCytomorphological criteria for the differential diagnosis of endometrial hyperplasia and endometrial cancer
Objective of the study: to establish an optimal set of cytological criteria and to develop a mathematical algorithm to improve the effectiveness of the differential diagnosis of endometrial hyperplasia and cancer.Materials and methods. A preoperative examination of the endometrium was carried out in 32 patients with abnormal uterine bleeding by means of aspiration cytology, using a standardized assessment algorithm comprising 7 most informative cytomorphological features. Based on mathematical analysis and Bayes’ theorem, an expert diagnostic system was developed, defining weighting coefficients and threshold values for differentiating between endometrial hyperplasia and endometrial cancer. The cytology findings were verified by the results of the post-operative histological examination.Results. The comprehensive use of standardized cytological criteria in combination with a mathematical algorithm improves the accuracy of the differential diagnosis of hyperplastic and malignant processes of the endometrium. The most significant cytological criteria for differential diagnosis were found to be impaired cell polarity within structures, an increased nuclear-cytoplasmic index, abnormal nuclear and nucleolar shapes, irregular nuclear membranes, neoplastic features and the formation of three-dimensional cell structures. In the group of women aged 30–39 years, a low prevalence of endometrial cancer was confirmed. The summary coefficient did not reach the threshold level. In the 40–49 age group, an increase in the frequency of endometrial hyperplastic processes, polyps and abnormal uterine bleeding was observed. It was in this group that the first case of endometrial carcinoma was recorded. In the patient with a malignant endometrial tumor, the summary diagnostic coefficient significantly exceeded the threshold value (+195), indicating the presence of a complex of cytomorphological features characteristic of malignant transformation of the endometrium. In women aged 60–69 years, endometrial pathology was represented by both glandular hyperplasia and endometrial cancer. The total diagnostic coefficient significantly exceeded the established diagnostic threshold.Conclusions. The results obtained support the comprehensive use of cytological criteria and a mathematical algorithm for differential diagnosis, which helps to improve the accuracy of detecting precancerous and malignant changes in the endometrium and may be recommended for implementation in cytology laboratories and clinical settings.
- Open Access
- 28 May 2026
- Published by Ternopil State Medical University in Актуальні питання педіатрії, акушерства та гінекології
- No. 1,p. 35-39
ХІРУРГІЧНА КОРЕКЦІЯ АПЛАЗІЇ ПІХВИ У ПАЦІЄНТОК ІЗ СИНДРОМОМ МАЙЄРА – РОКІТАНСЬКОГО – КЮСТЕРА – ГАУЗЕРА
Мета дослідження – оцінити ефективність лапароскопічних методів хірургічної корекції аплазії піхви у пацієнток із синдромом Майєра – Рокітанського – Кюстера – Гаузера шляхом оцінки найближчих і віддалених хірургічних результатів та сексуальної функції жінок. Матеріали та методи. Проведено аналіз результатів обстеження та лікування 32 пацієнток із синдромом Майєра – Рокітанського – Кюстера – Гаузера (MRKH). Контрольну групу склали 20 здорових жінок. Усім пацієнткам виконано хірургічне формування неовагіни із застосуванням лапароскопічних методик: 1 група (19 пацієнток) – перитонеальний кольпопоез (модифікована методика за Давидовим), 2 група (13 пацієнток) – кольпопоез із сигмоподібної кишки. Доопераційне обстеження включало клінічне, ультразвукове та, за показаннями, магнітно-резонансне дослідження органів малого таза. Оцінювали інтраопераційні показники, післяопераційні ускладнення, анатомічні та функціональні показники, індекс сексуальної функції у віддалений період. Результати дослідження та їх обговорення. У пацієнток обох досліджуваних груп досягнуто задовільного анатомічного результату з формуванням функціонально повноцінної неовагіни. Суттєвих відмінностей щодо кількості та спектра післяопераційних ускладнень, величини крововтрати, післяопераційної лихоманки та субфебрилітету, больового синдрому, тривалості операції, часу перебування в стаціонарі між основною групою і групою порівняння не було. Середня довжина сформованої неопіхви після операції становила в 1 групі (8,31±0,14) см, у 2 групі – (8,44±0,18) см (p>0,05). Індекс оцінки сексуальної функції через 12 місяців після операції показав порівнянні результати з контрольною групою: (26,66±0,28) бала в 1 групі проти (26,78±0,31) бала в 2 групі й (27,28±0,24) бала в контролі. Висновки. Сигмоїдальний та очеревинний кольпопоез забезпечують формування повноцінної неовагіни із добрими ранніми та пізніми післяопераційними анатомічними й функціональними результатами, які не мають суттєвих відмінностей у порівнюваних групах. Індивідуалізований вибір методу хірургічної реконструкції при синдромі Майєра – Рокітанського – Кюстера – Гаузера сприяє ефективному усуненню сексуальної дисфункції.
- 28 May 2026
- Published by Ternopil State Medical University in Актуальні питання педіатрії, акушерства та гінекології
- No. 1,p. 35-39
Open AccessХІРУРГІЧНА КОРЕКЦІЯ АПЛАЗІЇ ПІХВИ У ПАЦІЄНТОК ІЗ СИНДРОМОМ МАЙЄРА – РОКІТАНСЬКОГО – КЮСТЕРА – ГАУЗЕРА
Мета дослідження – оцінити ефективність лапароскопічних методів хірургічної корекції аплазії піхви у пацієнток із синдромом Майєра – Рокітанського – Кюстера – Гаузера шляхом оцінки найближчих і віддалених хірургічних результатів та сексуальної функції жінок. Матеріали та методи. Проведено аналіз результатів обстеження та лікування 32 пацієнток із синдромом Майєра – Рокітанського – Кюстера – Гаузера (MRKH). Контрольну групу склали 20 здорових жінок. Усім пацієнткам виконано хірургічне формування неовагіни із застосуванням лапароскопічних методик: 1 група (19 пацієнток) – перитонеальний кольпопоез (модифікована методика за Давидовим), 2 група (13 пацієнток) – кольпопоез із сигмоподібної кишки. Доопераційне обстеження включало клінічне, ультразвукове та, за показаннями, магнітно-резонансне дослідження органів малого таза. Оцінювали інтраопераційні показники, післяопераційні ускладнення, анатомічні та функціональні показники, індекс сексуальної функції у віддалений період. Результати дослідження та їх обговорення. У пацієнток обох досліджуваних груп досягнуто задовільного анатомічного результату з формуванням функціонально повноцінної неовагіни. Суттєвих відмінностей щодо кількості та спектра післяопераційних ускладнень, величини крововтрати, післяопераційної лихоманки та субфебрилітету, больового синдрому, тривалості операції, часу перебування в стаціонарі між основною групою і групою порівняння не було. Середня довжина сформованої неопіхви після операції становила в 1 групі (8,31±0,14) см, у 2 групі – (8,44±0,18) см (p>0,05). Індекс оцінки сексуальної функції через 12 місяців після операції показав порівнянні результати з контрольною групою: (26,66±0,28) бала в 1 групі проти (26,78±0,31) бала в 2 групі й (27,28±0,24) бала в контролі. Висновки. Сигмоїдальний та очеревинний кольпопоез забезпечують формування повноцінної неовагіни із добрими ранніми та пізніми післяопераційними анатомічними й функціональними результатами, які не мають суттєвих відмінностей у порівнюваних групах. Індивідуалізований вибір методу хірургічної реконструкції при синдромі Майєра – Рокітанського – Кюстера – Гаузера сприяє ефективному усуненню сексуальної дисфункції.
- Open Access
- 17 April 2026
- Published by Publishing Office TRILIST
- No. 82
Resolution of the VII International Forum of Experts on Menopausal Hormone Therapy
The VII International Forum of Experts on Menopausal Hormone Therapy (MHT) was held in Kyiv on November 18, 2025. The modern approach to the MHT prescription is not to resolve the issue of its appropriateness, but to choose the optimal form for a particular woman. Different routes of hormone administration have different pharmacokinetic properties and effects on metabolism, the coagulation system, and women’s somatic health. The recommendations of the European Menopause and Andropause Society emphasize the appropriateness of using combined MHT to improve the glycemic profile and delay the development of diabetes mellitus, with a preference for metabolically neutral progestogens – progesterone and dydrogesterone.Transdermal estrogens enter the systemic circulation directly, minimizing the effect on the liver and coagulation, which makes them the method of choice for women with an increased risk of venous thrombosis, obesity, or hypertriglyceridemia. At the same time, the effectiveness of transdermal MHT is characterized by significant interindividual variability.MHT is an effective antiresorptive method for the prevention of osteoporosis and fractures. Clinical studies demonstrate a significant increase in bone mineral density and a reduction in the risk of fractures with the use of MHT, particularly the combination of estradiol and dydrogesterone. Timely initiated MHT (within the first 10 years after menopause) is also associated with a decrease in all-cause mortality, cardiovascular complications, and neurodegenerative diseases. The individual choice of the form of MHT is a key factor in its safety and clinical efficacy.Particular attention should be paid to oncological safety, particularly the risk of breast cancer, when selecting MHT in patients using a levonorgestrel-releasing intrauterine system. Data from systematic reviews and meta-analyses indicate that the use of estrogens does not increase this risk, while it largely depends on the type of progestogen. Progesterone and dydrogesterone have the most favorable safety profile for the breast compared with synthetic gestagens, which is confirmed by the results of large-scale studies.Psychoemotional and sexual disorders (anxiety, depression, sleep disorders, and decreased libido) are common in perimenopause and are largely due to systemic estrogen deficiency, which affects neurometabolic, vascular, and neuroendocrine homeostasis. The high frequency of these disorders justifies the need for comprehensive diagnostic assessment and individualized MHT in perimenopausal women.
- 17 April 2026
- Published by Publishing Office TRILIST
- No. 82
Open AccessResolution of the VII International Forum of Experts on Menopausal Hormone Therapy
The VII International Forum of Experts on Menopausal Hormone Therapy (MHT) was held in Kyiv on November 18, 2025. The modern approach to the MHT prescription is not to resolve the issue of its appropriateness, but to choose the optimal form for a particular woman. Different routes of hormone administration have different pharmacokinetic properties and effects on metabolism, the coagulation system, and women’s somatic health. The recommendations of the European Menopause and Andropause Society emphasize the appropriateness of using combined MHT to improve the glycemic profile and delay the development of diabetes mellitus, with a preference for metabolically neutral progestogens – progesterone and dydrogesterone.Transdermal estrogens enter the systemic circulation directly, minimizing the effect on the liver and coagulation, which makes them the method of choice for women with an increased risk of venous thrombosis, obesity, or hypertriglyceridemia. At the same time, the effectiveness of transdermal MHT is characterized by significant interindividual variability.MHT is an effective antiresorptive method for the prevention of osteoporosis and fractures. Clinical studies demonstrate a significant increase in bone mineral density and a reduction in the risk of fractures with the use of MHT, particularly the combination of estradiol and dydrogesterone. Timely initiated MHT (within the first 10 years after menopause) is also associated with a decrease in all-cause mortality, cardiovascular complications, and neurodegenerative diseases. The individual choice of the form of MHT is a key factor in its safety and clinical efficacy.Particular attention should be paid to oncological safety, particularly the risk of breast cancer, when selecting MHT in patients using a levonorgestrel-releasing intrauterine system. Data from systematic reviews and meta-analyses indicate that the use of estrogens does not increase this risk, while it largely depends on the type of progestogen. Progesterone and dydrogesterone have the most favorable safety profile for the breast compared with synthetic gestagens, which is confirmed by the results of large-scale studies.Psychoemotional and sexual disorders (anxiety, depression, sleep disorders, and decreased libido) are common in perimenopause and are largely due to systemic estrogen deficiency, which affects neurometabolic, vascular, and neuroendocrine homeostasis. The high frequency of these disorders justifies the need for comprehensive diagnostic assessment and individualized MHT in perimenopausal women.
- Open Access
- 30 September 2025
- Published by Professional Event, LLC in Reproductive health of woman
- No. 6,p. 160-168
Endometrial stromal sarcoma: description of a rare clinical case
The rapid growth of uterine leiomyoma and disruption of its nutrition require differentiation from uterine sarcoma, although the incidence of sarcoma is about 1% of all malignant gynecological diseases. After myomectomy or hysterectomy, there is a 0.2–0.5% risk of detecting endometrial stromal sarcoma, and the differential diagnosis of cellular leiomyoma and sarcoma is difficult not only for clinicians but also for pathologists. Given the rarity and complexity of diagnosing endometrial stromal sarcoma, each case is of significant clinical and scientific interest.The article presents a clinical case of endometrial stromal sarcoma in a teenage girl. A 16-year-old female patient consulted her family doctor complaining of a fever of 38–39 °C for several days and general weakness. The examination revealed no changes in the lungs. She had regularly menses since the age of 12, but for the last 3 months her periods had been heavier and longer, leading to moderate anemia. An ultrasound examination, magnetic resonance imaging, and diagnostic laparoscopy at a children’s hospital led to a diagnosis of uterine fibroids. Due to suspected necrosis of the myomatous node, Pfannenstiel laparotomy and conservative myomectomy were performed. In the postoperative period, fever persisted, there was the resistance to anti-inflammatory and antibacterial therapy, as well as leukocytosis and lymphopenia, accompanied by increased levels of inflammation markers and the formation of hematoma and infiltrate in the abdominal cavity. The histological result indicate the low-grade endometrial stromal sarcoma; the material was sent for review and immunohistochemical (IHC) examination, which diagnosed high-grade endometrial stromal sarcoma.Given the histological diagnosis of sarcoma and the development of inflammatory complications, a decision was made to perform a hysterectomy with appendages, a biopsy of the greater omentum, and to change the antibiotic therapy in accordance with the sensitivity of the detected microorganism (Enterococcus faecium). Histological and IHC examinations of the removed uterus with appendages confirmed the presence of low-grade endometrial stromal sarcoma, positive for estrogen and progesterone receptors, with wild-type p53 expression and the presence of inflammatory changes. Positive clinical dynamics were observed in the postoperative period. The patient was discharged in satisfactory condition and referred to the National Cancer Institute of Ministry of Health of Ukraine, where she was consulted by a multidisciplinary team of specialists and diagnosed with low-grade endometrial stromal sarcoma T1N0M0 stage 1, clinical group 2. Megestrol acetate at a dose of 160 mg was prescribed as adjuvant therapy for 2 years. Follow-up computed tomography of the chest, abdomen, and pelvis 3 and 6 months after surgery showed no signs of disease progression.Conclusions. Endometrial stromal sarcoma is a rare malignant uterine tumor that can mimic the clinical picture of leiomyoma, especially in young patients. Differential diagnosis between cellular leiomyoma and uterine sarcoma is difficult even for experienced morphologists, which necessitates the use of IHC methods. The presence of rapid tumor growth and signs of impaired nutrition requires cancer awareness and careful preoperative examination. A multidisciplinary approach of surgical treatment, pathomorphological confirmation, and adjuvant hormonal therapy contributes to the achievement of favorable short-term results.
- 30 September 2025
- Published by Professional Event, LLC in Reproductive health of woman
- No. 6,p. 160-168
Open AccessEndometrial stromal sarcoma: description of a rare clinical case
The rapid growth of uterine leiomyoma and disruption of its nutrition require differentiation from uterine sarcoma, although the incidence of sarcoma is about 1% of all malignant gynecological diseases. After myomectomy or hysterectomy, there is a 0.2–0.5% risk of detecting endometrial stromal sarcoma, and the differential diagnosis of cellular leiomyoma and sarcoma is difficult not only for clinicians but also for pathologists. Given the rarity and complexity of diagnosing endometrial stromal sarcoma, each case is of significant clinical and scientific interest.The article presents a clinical case of endometrial stromal sarcoma in a teenage girl. A 16-year-old female patient consulted her family doctor complaining of a fever of 38–39 °C for several days and general weakness. The examination revealed no changes in the lungs. She had regularly menses since the age of 12, but for the last 3 months her periods had been heavier and longer, leading to moderate anemia. An ultrasound examination, magnetic resonance imaging, and diagnostic laparoscopy at a children’s hospital led to a diagnosis of uterine fibroids. Due to suspected necrosis of the myomatous node, Pfannenstiel laparotomy and conservative myomectomy were performed. In the postoperative period, fever persisted, there was the resistance to anti-inflammatory and antibacterial therapy, as well as leukocytosis and lymphopenia, accompanied by increased levels of inflammation markers and the formation of hematoma and infiltrate in the abdominal cavity. The histological result indicate the low-grade endometrial stromal sarcoma; the material was sent for review and immunohistochemical (IHC) examination, which diagnosed high-grade endometrial stromal sarcoma.Given the histological diagnosis of sarcoma and the development of inflammatory complications, a decision was made to perform a hysterectomy with appendages, a biopsy of the greater omentum, and to change the antibiotic therapy in accordance with the sensitivity of the detected microorganism (Enterococcus faecium). Histological and IHC examinations of the removed uterus with appendages confirmed the presence of low-grade endometrial stromal sarcoma, positive for estrogen and progesterone receptors, with wild-type p53 expression and the presence of inflammatory changes. Positive clinical dynamics were observed in the postoperative period. The patient was discharged in satisfactory condition and referred to the National Cancer Institute of Ministry of Health of Ukraine, where she was consulted by a multidisciplinary team of specialists and diagnosed with low-grade endometrial stromal sarcoma T1N0M0 stage 1, clinical group 2. Megestrol acetate at a dose of 160 mg was prescribed as adjuvant therapy for 2 years. Follow-up computed tomography of the chest, abdomen, and pelvis 3 and 6 months after surgery showed no signs of disease progression.Conclusions. Endometrial stromal sarcoma is a rare malignant uterine tumor that can mimic the clinical picture of leiomyoma, especially in young patients. Differential diagnosis between cellular leiomyoma and uterine sarcoma is difficult even for experienced morphologists, which necessitates the use of IHC methods. The presence of rapid tumor growth and signs of impaired nutrition requires cancer awareness and careful preoperative examination. A multidisciplinary approach of surgical treatment, pathomorphological confirmation, and adjuvant hormonal therapy contributes to the achievement of favorable short-term results.
- Open Access
- 18 September 2025
- Published by Publishing Office TRILIST in Reproductive Endocrinology
- No. 79,p. 18-28
Resolution of the II Ukrainian Forum of Experts on Endometriosis
Endometriosis is a chronic, incurable disease that requires a long-term and individualized approach to the management of patients from menarche to menopause. This disease significantly reduces the quality of life of most patients, affects sexual and family life, is the cause of infertility and increases the risk of ovarian cancer in older age. In addition to physical discomfort, endometriosis has a significant negative impact on mental health, causing the development of depression and anxiety, which can aggravate chronic pelvic pain.In Ukraine, work is underway to update the national clinical protocol for the management of endometriosis. The working group, approved by the order of the Ministry of Health of Ukraine, uses the updated NICE (2024) and ESHRE (2022) guidelines to prepare current regulatory documents. The goal is to standardize approaches, take into account the latest scientific data and comprehensive management, which includes, in addition to medical aspects, also reproductive and social rehabilitation.The ESHRE (2022) and NICE (2024) guidelines move away from laparoscopy as the “gold standard” of diagnosis. Instead, they emphasize the importance of clinical examination, imaging (ultrasound, MRI) and empirical treatment.Drug therapy should be aimed at controlling symptoms. It is important to take into account individual characteristics, patient wishes, side effect profile and cost. Dydrogesterone has been recognized as effective and safe for the treatment of endometriosis-associated pain, especially in patients who wish to plan a pregnancy, since it does not suppress ovulation. Nonsteroidal anti-inflammatory drugs, including high doses of ibuprofen, may be used to relieve pain.Surgery involves removing the endometriosis lesions and is an important tool in cases of ineffective pharmacotherapy. However, surgery does not guarantee complete pain relief and has a high risk of recurrence, especially in young women. Repeated operations can significantly reduce ovarian reserve.For women with endometriosis-related infertility, assisted reproductive technologies, including in vitro fertilization, can be used. The endometriosis fertility index is a useful tool for deciding on the optimal method of achieving pregnancy.For successful management of patients, it is critical to develop a long-term plan that includes medical and surgical interventions, lifestyle modification, and the integration of psychological support. Raising women’s awareness of their condition, along with cognitive-behavioral therapy, and relaxation techniques, has been proven effective in reducing pain and improving the quality of life of such patients.
- 18 September 2025
- Published by Publishing Office TRILIST in Reproductive Endocrinology
- No. 79,p. 18-28
Open AccessResolution of the II Ukrainian Forum of Experts on Endometriosis
Endometriosis is a chronic, incurable disease that requires a long-term and individualized approach to the management of patients from menarche to menopause. This disease significantly reduces the quality of life of most patients, affects sexual and family life, is the cause of infertility and increases the risk of ovarian cancer in older age. In addition to physical discomfort, endometriosis has a significant negative impact on mental health, causing the development of depression and anxiety, which can aggravate chronic pelvic pain.In Ukraine, work is underway to update the national clinical protocol for the management of endometriosis. The working group, approved by the order of the Ministry of Health of Ukraine, uses the updated NICE (2024) and ESHRE (2022) guidelines to prepare current regulatory documents. The goal is to standardize approaches, take into account the latest scientific data and comprehensive management, which includes, in addition to medical aspects, also reproductive and social rehabilitation.The ESHRE (2022) and NICE (2024) guidelines move away from laparoscopy as the “gold standard” of diagnosis. Instead, they emphasize the importance of clinical examination, imaging (ultrasound, MRI) and empirical treatment.Drug therapy should be aimed at controlling symptoms. It is important to take into account individual characteristics, patient wishes, side effect profile and cost. Dydrogesterone has been recognized as effective and safe for the treatment of endometriosis-associated pain, especially in patients who wish to plan a pregnancy, since it does not suppress ovulation. Nonsteroidal anti-inflammatory drugs, including high doses of ibuprofen, may be used to relieve pain.Surgery involves removing the endometriosis lesions and is an important tool in cases of ineffective pharmacotherapy. However, surgery does not guarantee complete pain relief and has a high risk of recurrence, especially in young women. Repeated operations can significantly reduce ovarian reserve.For women with endometriosis-related infertility, assisted reproductive technologies, including in vitro fertilization, can be used. The endometriosis fertility index is a useful tool for deciding on the optimal method of achieving pregnancy.For successful management of patients, it is critical to develop a long-term plan that includes medical and surgical interventions, lifestyle modification, and the integration of psychological support. Raising women’s awareness of their condition, along with cognitive-behavioral therapy, and relaxation techniques, has been proven effective in reducing pain and improving the quality of life of such patients.
- Open Access
- 18 September 2025
- Published by Publishing Office TRILIST in Reproductive Endocrinology
- No. 79,p. 8-16
Resolution of the III Ukrainian Forum of Experts on Abnormal Uterine Bleeding
Abnormal uterine bleeding (AUB) is the leading reason for seeking medical attention among women aged 30 to 50. Given the demographic crisis that Ukraine is currently facing, there is an urgent need to develop a strategy to preserve the reproductive health of the population and update the national regulatory framework. This should take into account modern scientific achievements to unify clinical approaches.The resolution of this Forum aims to improve clinical approaches to the management of patients with menstrual disorders and AUB, to implement personalized treatment, which is designed to improve the reproductive health of Ukrainian women in conditions of full-scale war.The resolution summarizes the recommendations of international associations, highlights the advantages of using gestagens in the treatment of AUB, applies an interdisciplinary approach to discussing AUB management - from hematological and endocrinological perspectives, and considers the issue of prevention of venous thromboembolic complications in gynecological patients. In order to optimize the management of patients with AUB, the Forum experts improved the AUB management algorithm. The main difference was the clarification of the period for which the patient has a request and willingness to take contraceptives.The main direction of AUB pharmacotherapy is the use of hormonal drugs such as combined oral contraceptives and gestagens. Among gestagens, high efficacy and safety of dydrogesterone has been proven. Given the fact that most patients with AUB have concomitant pathology, interdisciplinary cooperation and integration of a patient-oriented approach are important, which is the key to preserving the reproductive potential of Ukrainian women.
- 18 September 2025
- Published by Publishing Office TRILIST in Reproductive Endocrinology
- No. 79,p. 8-16
Open AccessResolution of the III Ukrainian Forum of Experts on Abnormal Uterine Bleeding
Abnormal uterine bleeding (AUB) is the leading reason for seeking medical attention among women aged 30 to 50. Given the demographic crisis that Ukraine is currently facing, there is an urgent need to develop a strategy to preserve the reproductive health of the population and update the national regulatory framework. This should take into account modern scientific achievements to unify clinical approaches.The resolution of this Forum aims to improve clinical approaches to the management of patients with menstrual disorders and AUB, to implement personalized treatment, which is designed to improve the reproductive health of Ukrainian women in conditions of full-scale war.The resolution summarizes the recommendations of international associations, highlights the advantages of using gestagens in the treatment of AUB, applies an interdisciplinary approach to discussing AUB management - from hematological and endocrinological perspectives, and considers the issue of prevention of venous thromboembolic complications in gynecological patients. In order to optimize the management of patients with AUB, the Forum experts improved the AUB management algorithm. The main difference was the clarification of the period for which the patient has a request and willingness to take contraceptives.The main direction of AUB pharmacotherapy is the use of hormonal drugs such as combined oral contraceptives and gestagens. Among gestagens, high efficacy and safety of dydrogesterone has been proven. Given the fact that most patients with AUB have concomitant pathology, interdisciplinary cooperation and integration of a patient-oriented approach are important, which is the key to preserving the reproductive potential of Ukrainian women.
- Open Access
- 31 July 2025
- Published by Professional Event, LLC in Reproductive health of woman
- No. 5,p. 112-117
The problem of infertility and oocyte quality in endometriosis
Endometriosis is a common chronic estrogen-dependent inflammatory disease that impairs a woman’s reproductive function. Subfertility in endometriosis is associated with genetic and anatomical factors, activation of pro-inflammatory cytokines, uterine dysperistalsis, impaired endometrial implantation capacity, reduced ovarian reserve, especially after surgical interventions for ovarian endometriomas, and possibly impaired oocyte and embryo quality.An analysis of current open databases PubMed, MEDLINE, Scopus, ScienceDirect, Cochrane Library showed that there is currently insufficient evidence to prove or disprove the negative impact of endometriosis on oocyte quality. The number of antral follicles, the number and quality of oocytes and embryos obtained, and the fertilisation rate in patients with endometriosis did not differ significantly in one group of studies, while in another group there was a significantly reduced ovarian reserve, oocyte yield and number of mature oocytes. Evidence suggests that oocytes obtained from women with endometriosis more often have altered morphology, they are characterized by failed in vitro maturation and lower mitochondrial content, morphological abnormalities in the cytoplasm, zona pellucida, and the first polar body in the cytoplasm compared to women with other causes of infertility. The lower number of metaphase II oocytes, the lower total number of embryos and high-quality embryos, and the lower cumulative clinical pregnancy rate may be associated with lower oocyte yield, although a clear clinical impact on pregnancy has not yet been confirmed. The lack of consensus is partly due to the use of different morphological parameters, indirect assessment methods, such as granulosa cell status, follicular fluid volume, etc., to assess oocyte quality, which makes it difficult to determine and compare the results of different studies.Conclusions. The problem of infertility in endometriosis is a complex and multifaceted one and requires further research to determine the influence of phenotype and stage of endometriosis, extent of surgical intervention, ovarian reserve, standardisation of the assessment of the qualitative characteristics of oocytes and embryos on reproductive outcomes.
- 31 July 2025
- Published by Professional Event, LLC in Reproductive health of woman
- No. 5,p. 112-117
Open AccessThe problem of infertility and oocyte quality in endometriosis
Endometriosis is a common chronic estrogen-dependent inflammatory disease that impairs a woman’s reproductive function. Subfertility in endometriosis is associated with genetic and anatomical factors, activation of pro-inflammatory cytokines, uterine dysperistalsis, impaired endometrial implantation capacity, reduced ovarian reserve, especially after surgical interventions for ovarian endometriomas, and possibly impaired oocyte and embryo quality.An analysis of current open databases PubMed, MEDLINE, Scopus, ScienceDirect, Cochrane Library showed that there is currently insufficient evidence to prove or disprove the negative impact of endometriosis on oocyte quality. The number of antral follicles, the number and quality of oocytes and embryos obtained, and the fertilisation rate in patients with endometriosis did not differ significantly in one group of studies, while in another group there was a significantly reduced ovarian reserve, oocyte yield and number of mature oocytes. Evidence suggests that oocytes obtained from women with endometriosis more often have altered morphology, they are characterized by failed in vitro maturation and lower mitochondrial content, morphological abnormalities in the cytoplasm, zona pellucida, and the first polar body in the cytoplasm compared to women with other causes of infertility. The lower number of metaphase II oocytes, the lower total number of embryos and high-quality embryos, and the lower cumulative clinical pregnancy rate may be associated with lower oocyte yield, although a clear clinical impact on pregnancy has not yet been confirmed. The lack of consensus is partly due to the use of different morphological parameters, indirect assessment methods, such as granulosa cell status, follicular fluid volume, etc., to assess oocyte quality, which makes it difficult to determine and compare the results of different studies.Conclusions. The problem of infertility in endometriosis is a complex and multifaceted one and requires further research to determine the influence of phenotype and stage of endometriosis, extent of surgical intervention, ovarian reserve, standardisation of the assessment of the qualitative characteristics of oocytes and embryos on reproductive outcomes.
- Open Access
- 30 June 2025
- Published by Professional Event, LLC in Reproductive health of woman
- No. 4,p. 60-65
Effectiveness of laparoscopic correction of niche after cesarean section
The frequency of niche after cesarean section (NACS) is 25–85% and depends on many factors, increasing with each next cesarean section, which can cause chronic abnormal uterine bleeding, pelvic pain, subfertility.The objective: to evaluate the immediate and long-term results of the developed method of laparoscopic correction of symptomatic NACS.Materials and methods. During 2022–2024, 58 patients of reproductive age were prospectively observed in the clinics of the Odesa National Medical University: 28 women (main group) with a NACS and 30 practically healthy women of the same age with a uterine scar who were examined for male factor infertility (control group). A comprehensive assessment of the uterine scar, length, depth, width of the niche, and thickness of the residual myometrium was performed using ultrasound examonation. The histological structure of the endometrium and myometrium was studied. All patients in the main group underwent laparoscopic isthmoplasty using the developed technique (two-row separate Vicryl (2.0) sutures with delayed tying of 1 row of sutures).Results. The niche was visualized by transvaginal ultrasound examination as a defect in the myometrium in the anterior uterine wall of a triangular, oval or irregular shape, with a depth of 6.3 ± 1.6 mm, the thickness of the residual myometrium was from 2 to 4 mm, on average 3.0 ± 0.3 mm. The most frequent symptoms of the NACS were menorrhagia – 35.7%, intermenstrual bleeding – 32.1%, perimenstrual spotting – 67.9%, chronic pelvic pain – 57.1%, dysmenorrhea – 64.3%, dyspareunia – 53.6%, chronic vaginal discharge – 28.6% and subfertility – 53.6% of cases. Laparoscopic isthmoplasty according to the developed technique after 3 months after surgery contributed to a significant reduction in the frequency of menorrhagia by 3.3 times (p < 0.01), intermenstrual bleeding by 3.0 times (p < 0.01), perimenstrual spotting by 3.2 times (p < 0.01), as well as chronic pelvic pain by 2.7 times (p < 0.01), dysmenorrhea by 2.2 times (p < 0.05), dyspareunia by 2.5 times (p < 0.05), chronic vaginal discharge with a stable clinical effect 6 and 12 months after surgery. The thickness of the residual myometrium after laparoscopic isthmoplasty increased from 3.0 ± 0.6 to 4.5 ± 0.4 mm after 3 months, to 5.2 ± 0.6 mm after 6 months and up to 5.9 ± 0.5 mm 12 months after laparoscopic treatment (p < 0.01).Conclusions. Laparoscopic correction of symptomatic NACS using the developed technique helps to reduce symptoms of abnormal uterine bleeding, pelvic pain, increase the thickness of the residual myometrium, and improves the pregnancy rate in patients with subfertility.
- 30 June 2025
- Published by Professional Event, LLC in Reproductive health of woman
- No. 4,p. 60-65
Open AccessEffectiveness of laparoscopic correction of niche after cesarean section
The frequency of niche after cesarean section (NACS) is 25–85% and depends on many factors, increasing with each next cesarean section, which can cause chronic abnormal uterine bleeding, pelvic pain, subfertility.The objective: to evaluate the immediate and long-term results of the developed method of laparoscopic correction of symptomatic NACS.Materials and methods. During 2022–2024, 58 patients of reproductive age were prospectively observed in the clinics of the Odesa National Medical University: 28 women (main group) with a NACS and 30 practically healthy women of the same age with a uterine scar who were examined for male factor infertility (control group). A comprehensive assessment of the uterine scar, length, depth, width of the niche, and thickness of the residual myometrium was performed using ultrasound examonation. The histological structure of the endometrium and myometrium was studied. All patients in the main group underwent laparoscopic isthmoplasty using the developed technique (two-row separate Vicryl (2.0) sutures with delayed tying of 1 row of sutures).Results. The niche was visualized by transvaginal ultrasound examination as a defect in the myometrium in the anterior uterine wall of a triangular, oval or irregular shape, with a depth of 6.3 ± 1.6 mm, the thickness of the residual myometrium was from 2 to 4 mm, on average 3.0 ± 0.3 mm. The most frequent symptoms of the NACS were menorrhagia – 35.7%, intermenstrual bleeding – 32.1%, perimenstrual spotting – 67.9%, chronic pelvic pain – 57.1%, dysmenorrhea – 64.3%, dyspareunia – 53.6%, chronic vaginal discharge – 28.6% and subfertility – 53.6% of cases. Laparoscopic isthmoplasty according to the developed technique after 3 months after surgery contributed to a significant reduction in the frequency of menorrhagia by 3.3 times (p < 0.01), intermenstrual bleeding by 3.0 times (p < 0.01), perimenstrual spotting by 3.2 times (p < 0.01), as well as chronic pelvic pain by 2.7 times (p < 0.01), dysmenorrhea by 2.2 times (p < 0.05), dyspareunia by 2.5 times (p < 0.05), chronic vaginal discharge with a stable clinical effect 6 and 12 months after surgery. The thickness of the residual myometrium after laparoscopic isthmoplasty increased from 3.0 ± 0.6 to 4.5 ± 0.4 mm after 3 months, to 5.2 ± 0.6 mm after 6 months and up to 5.9 ± 0.5 mm 12 months after laparoscopic treatment (p < 0.01).Conclusions. Laparoscopic correction of symptomatic NACS using the developed technique helps to reduce symptoms of abnormal uterine bleeding, pelvic pain, increase the thickness of the residual myometrium, and improves the pregnancy rate in patients with subfertility.
- Open Access
- 1 January 2025
- Published by Publishing House Helvetica (Publications)
- No. 5,p. 56-60
CHANGES OF PROTEIN EXPRESSION OF PLATINUM RESISTANCE INDICATORS UNDER THE INFLUENCE OF HYPERTHERMIA DURING THE HIPEC PROCEDURE IN RECURRENT OVARIAN CANCER
Introduction. Ovarian cancer relapse and death are usually caused by acquired drug resistance. The mechanisms of platinum resistance are multifactorial. Excision repair cross-complementation group 1 (ERCC1) is a protein critical in removing platinum-induced DNA lesions. Microsatellite Instability (MSI) is present in a substantial proportion of ovarian cancers but knowledge about its clinical value is limited. Hyperthermia, one more promising treatment agent, delays the repair of DNA damage. Hyperthermic intraperitoneal chemoperfusion (HIPEC), which has been actively studied in recent years as a possible addition to therapy for advanced stages of epithelial ovarian cancer. Material and methods. The study was retrospective, it included a total of 16 patients with stage IIIC epithelial ovarian cancer. For various reasons, these patients underwent suboptimal cytoreductive surgery with HIPEC + Second-look surgery with complete / optimal cytoreduction (6 patients) or relaparotomy with biopsy of residual disease due to surgical complications in 2–4 weeks interval. Immunohistochemical investigation of ERCC1 and MLH-1 expression were performed for the histological samples obtained from pre- and post HIPEC metastatic tumor tissue on the first and second surgical interventions. Conclusions. DNA repair pathways are one of the most important factors of platinum drug resistance formation. Hyperthermia during HIPEC procedure leads to decrease in the efficiency of DNA repair pathways by reducing the expression of ERCC1 and MMR proteins. These changes may determine the proven effectiveness of HIPEC procedure with cytoreduction after NACT (which may lead to secondary platinum drug resistance formation) by overcoming platinum resistance. Рецидив раку яєчників і подальша смерть зазвичай спричинені набутою медикаментозною резистентністю. Механізми резистентності до платини багатофакторні. Шляхи репарації ДНК є одним із найважливіших факторів формування стійкості до препаратів платини. Гіпертермія під час процедури HIPEC призводить до зниження ефективності репарації ДНК шляхом зменшення експресії ERCC1 (з 57,56% клітин до 5% клітин – p < 0,05) та білків MLH-1 (з 9,11% клітин до 0% клітин – p < 0,05). Цей механізм подолання вторинної резистентності до препаратів платини обґрунтовує ефективність процедури HIPEC з циторедукцією після неоадʼювантної хіміотерапії.
- 1 January 2025
- Published by Publishing House Helvetica (Publications)
- No. 5,p. 56-60
Open AccessCHANGES OF PROTEIN EXPRESSION OF PLATINUM RESISTANCE INDICATORS UNDER THE INFLUENCE OF HYPERTHERMIA DURING THE HIPEC PROCEDURE IN RECURRENT OVARIAN CANCER
Introduction. Ovarian cancer relapse and death are usually caused by acquired drug resistance. The mechanisms of platinum resistance are multifactorial. Excision repair cross-complementation group 1 (ERCC1) is a protein critical in removing platinum-induced DNA lesions. Microsatellite Instability (MSI) is present in a substantial proportion of ovarian cancers but knowledge about its clinical value is limited. Hyperthermia, one more promising treatment agent, delays the repair of DNA damage. Hyperthermic intraperitoneal chemoperfusion (HIPEC), which has been actively studied in recent years as a possible addition to therapy for advanced stages of epithelial ovarian cancer. Material and methods. The study was retrospective, it included a total of 16 patients with stage IIIC epithelial ovarian cancer. For various reasons, these patients underwent suboptimal cytoreductive surgery with HIPEC + Second-look surgery with complete / optimal cytoreduction (6 patients) or relaparotomy with biopsy of residual disease due to surgical complications in 2–4 weeks interval. Immunohistochemical investigation of ERCC1 and MLH-1 expression were performed for the histological samples obtained from pre- and post HIPEC metastatic tumor tissue on the first and second surgical interventions. Conclusions. DNA repair pathways are one of the most important factors of platinum drug resistance formation. Hyperthermia during HIPEC procedure leads to decrease in the efficiency of DNA repair pathways by reducing the expression of ERCC1 and MMR proteins. These changes may determine the proven effectiveness of HIPEC procedure with cytoreduction after NACT (which may lead to secondary platinum drug resistance formation) by overcoming platinum resistance. Рецидив раку яєчників і подальша смерть зазвичай спричинені набутою медикаментозною резистентністю. Механізми резистентності до платини багатофакторні. Шляхи репарації ДНК є одним із найважливіших факторів формування стійкості до препаратів платини. Гіпертермія під час процедури HIPEC призводить до зниження ефективності репарації ДНК шляхом зменшення експресії ERCC1 (з 57,56% клітин до 5% клітин – p < 0,05) та білків MLH-1 (з 9,11% клітин до 0% клітин – p < 0,05). Цей механізм подолання вторинної резистентності до препаратів платини обґрунтовує ефективність процедури HIPEC з циторедукцією після неоадʼювантної хіміотерапії.